GERMANY PROPOSES SIX Rx-TO-OTC SWITCHES EFFECTIVE JAN. 1, 1995
This article was originally published in The Tan Sheet
Executive Summary
GERMANY PROPOSES SIX Rx-TO-OTC SWITCHES EFFECTIVE JAN. 1, 1995, including two topical nonsteroidal anti-inflammatory drugs indicated for local antirheumatic therapy -- felbinac and flufenamic. Lederle, which is developing topical felbinac as a prescription drug in the U.S., will market the nonprescription product in Germany. Luitpold, a subsidiary of Japan-based Sankyo, will market a flufenamic product. The proposal for nonprescription status of these two products follows the July 1 effective switch date of two other topical NSAIDs -- etofenamate and piroxicam.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning